Aktienanalyse zu Recursion Pharmaceuticals Inc (RXRX)RXRXRecursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Recursion Pharmaceuticals Inc is a good buy right now due to its recent price increase of 5.83% over the last five days and a current price of $4.36, which is below the analyst price target of $5.50. Additionally, the stock has shown a positive momentum with an RSI of 57.036, indicating it is not overbought yet. However, investors should be cautious of the significant net loss of $131 million reported in Q2 2026, which poses a risk to future profitability.